Ribomic
4591.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥3m | ¥2m | — | ¥66m | ¥81m | ¥92m |
| Operating income | −¥1.2bn | −¥1.1bn | −¥1.1bn | −¥1.8bn | −¥1.7bn | −¥1.2bn |
| Ordinary income | −¥1.1bn | −¥1.0bn | −¥983m | −¥1.6bn | −¥1.6bn | −¥1.2bn |
| Total assets | ¥3.0bn | ¥3.2bn | ¥3.5bn | ¥4.6bn | ¥5.0bn | ¥6.1bn |
| Net assets / equity | ¥2.8bn | ¥3.0bn | ¥3.4bn | ¥4.4bn | ¥4.7bn | ¥6.0bn |
| Operating cash flow | −¥1.1bn | −¥997m | −¥933m | −¥1.7bn | −¥1.5bn | −¥1.1bn |
| EPS (basic) | ¥-23.07 | ¥-25.21 | ¥-28.7 | ¥-53.14 | ¥-59.95 | ¥-46.17 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 104 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 63 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 104 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 59 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 104 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 39 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 59 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 37 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 105 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 39 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 59 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 37 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 105 figures · EDINET |
23 more reports are still being processed.